DiaSorin S p A : CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM

DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM

• DIASORIN - THROUGH ITS ITALIAN SUBSIDIARY DIASORIN ITALIA S.P.A. - POSITIONS ITSELF AS DISTRIBUTOR OF MEMED BV® TEST IN ITALY ON THE MEMED KEY® PLATFORM IN DECENTRALIZED TERRITORIAL HEALTHCARE SETTINGS
• MEMED BV® TEST ENABLES RAPID DIFFERENTIATION BETWEEN BACTERIAL AND VIRAL INFECTIONS, THEREBY SUPPORTING BETTER-INFORMED ANTIBIOTIC TREATMENT DECISIONS

Saluggia, Italy, 26 May 2023 - DiaSorin (FTSE MIB: DIA), through its subsidiary DiaSorin Italia S.p.A., consolidates its strategic partnership with MeMed, by signing a distribution agreement for the Italian market of MeMed BV® test on the MeMed Key® analytical platform.

DiaSorin Italia S.p.A. will offer the MeMed BV® diagnostic solution on the proprietary LIAISON® XL and LIAISON® XS platforms, which are already present in centralized laboratories for high- throughput testing, as well as on the MeMed Key® platform, designed to meet the demands on smaller footprint instrumentation and compatible with new decentralized healthcare realities on the territory1.

MeMed BV® test:

• integrates artificial intelligence algorithms with measurements of three key host-immune proteins (TRAIL2, IP-103 and C-reactive protein) linked to patient's immune response, enabling physicians to rapidly differentiate bacterial from viral infections, thereby supporting better-informed antibiotic treatment decisions;
• has the potential to transform the therapeutic management of patients;
• is developed and validated by MeMed in collaboration with leading academic and commercial partners;
• is validated in multi-national,double-blind clinical studies and real-world settings on over 20,000 patients in Italy, Israel, United States and other European countries, demonstrating over 90% of sensitivity and specificity (NPV>98%) in differentiating between bacterial and viral infections;
• has received CE mark in Europe, AMAR clearance from Israeli Ministry of Health and U.S. FDA 510(k) clearance.

"The new agreement signed with MeMed reinforces DiaSorin's commitment to combating antimicrobial resistance, a growing global threat. Differentiating bacterial from viral infections is, in fact, one of the most significant healthcare challenges we must address," said Ugo Gay, Managing Director and General Manager of DiaSorin Italia. "Clinical anamnesis, physical examination and traditional diagnostic tests may not provide complete and timely results, thus not providing clear indication of infection, which can jeopardize or delay patient treatment and lead to increased misuse of antibiotics".

1. Italian Decree Law no.77 of May 23, 2022
2. tumor necrosis factor-relatedapoptosis-inducing ligand
3. interferon gamma induced protein-10

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 41 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist."

More info atwww.diasoringroup.com

About MeMed

Our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. Follow and connect with MeMed via LinkedIn,Twitter,and Facebook.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT: